Intriguingly, the novel antidiabetic drug and SGLT2 inhibitor empagliflozin attenuate renal hyperfiltration in subjects with type 1 diabetes [20], suggesting the potential role of SGLT2 inhibitors in renoprotection in diabetic kidneys by inhibiting proximal tubular oxygen consumption. The gene discussed is SLC5A2; the disease is type 1 diabetes mellitus.